高选择性HPK1抑制剂NDI-101150调解免疫细胞激活和强大的抗瘤反应,与免疫检查点封锁不同
David N Ciccone1, Fu-Shan Kuo1, Scott Boiko1
1Nimbus Therapeutics Inc, Boston, Massachusetts, USA.
Journal for immunotherapy of cancer
|July 30, 2025
概括
一种新的小分子抑制剂,NDI-101150,向造血原体基因酶1 (HPK1) 激活免疫细胞. 这种免疫瘤疗法表现出强大的抗瘤作用,并诱导免疫记忆.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 血液生成原始基因酶1 (HPK1) 是一种血清/氨酸基因酶,可以负面调节免疫细胞功能.
- 在小鼠中禁用HPK1可增强免疫细胞活性并抑制瘤生长,这表明HPK1是免疫瘤学的治疗点.
研究的目的:
- 确定和描述HPK1激酶活性的强效和选择性小分子抑制剂.
- 在临床前癌症模型中评估HPK1抑制剂NDI-101150的疗效.
主要方法:
- 采用结构导向药物设计方法来发现NDI-101150.0.
- 评估了NDI-101150在体外和体内不同免疫细胞的作用.
主要成果:
- NDI-101150增强了T细胞,B细胞和树突细胞的激活,即使在免疫抑制条件下或抗PD-1疗法无效的情况下.
- 在多个模型中,NDI-101150显示出显著的瘤生长抑制,包括那些对抗PD-1耐药的模型.
- 抑制剂在瘤再次挑战时诱导了持久的抗瘤免疫记忆.
结论:
- 小分子抑制HPK1激酶导致广泛的免疫细胞激活.
- 这种激活导致有效的抗瘤免疫反应,突出了NDI-101150作为免疫瘤治疗的潜力.
相关概念视频
01:27Cytotoxic T Cells-mediated Immune Response
2.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.1K
01:27Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
262
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
262
01:28Cells of the Innate Immune Response
3.3K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
3.3K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K